BrightSpring Health Services (BTSG) told investors Thursday that its turnaround remains in the early innings, even as the company boasts an $11.6 billion valuation and a 105% total return over the past year.
Speaking at the third annual Bernstein Healthcare Forum, BrightSpring's leadership outlined segment-level growth, a massive acquisition history, and an expanding AI effort. The company serves more than 450,000 patients daily across its pharmacy and provider-services businesses.
Provider services posted the sharpest gains, rising more than 30% in the trailing twelve months after registering nearly 20% year-over-year growth in the second quarter. Home healthcare and rehabilitation both grew at mid-teens rates, while personal care and the home-and-community pharmacy lines lagged in the low to mid-single digits—the slowest-growth provider line.
Beyond services, BrightSpring launches roughly 16 to 20 limited-distribution drugs each year, a process that typically takes two to four years to reach full contribution. Its specialty-pharmacy operation distinguishes itself through speed and adherence: the time from prescription to first-fill averages about four days, roughly half the industry mean, while medication possession ratios sit in the mid-90s percentage range and patient net promoter scores consistently exceed 90.
CFO Jen Phipps and Head of Investor Relations David Deuchler were frank that integration progress is still nascent across the enterprise. "We're serving similar patients in similar settings," Deuchler said, noting the vast runway to deepen cross-segment penetration among the company's patient base.
BrightSpring has financed much of that expansion through deals. It has completed approximately 80 acquisitions over the past decade and is set to close a December purchase of divested Amedisys and LHC Group assets. A partnership with an Accountable Care Organization is slated to begin in 2027, with management expecting a more meaningful step-up in 2028.
On the technology front, BrightSpring employs nearly 30 people on its artificial-intelligence team, led by a chief technology officer who previously held roles at Google, CoreWeave, and healthcare payer companies. Among early wins, AI tools have compressed consultant-pharmacist medication reconciliations from 15 to 20 separate screens into a streamlined single workflow.
The stock was trading around $56.55 as of late September, giving the company a return on equity of roughly 13% over the past year.
